This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walzer, P. D.
Right arrow Articles by Ashbaugh, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walzer, P. D.
Right arrow Articles by Ashbaugh, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 514-516, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.514-516.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia

Peter D. Walzer1,2* and Alan Ashbaugh2

Research Service, Veterans Affairs Medical Center, Cincinnati, Ohio 45220,1 Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 452672

Received 7 August 2001/ Returned for modification 27 September 2001/ Accepted 22 October 2001

Terbinafine, an allylamine used to treat onychomycosis, has been reported to be active against rat Pneumocystis carinii in vitro and in vivo. By contrast, our in vitro data showed that the 50% inhibitory concentration of terbinafine against rat P. carinii is 3.7 µg/ml, a level that cannot be clinically achieved in serum. In the present study, terbinafine administered orally at doses of 20 to 400 mg/kg/day and 50 to 250 mg/kg/day was ineffective therapy for mouse and rat models of pneumocystosis, respectively. These results emphasize the complexities of P. carinii drug testing and the need for caution before considering studies in humans.

* Corresponding author. Mailing address: Research Service (151), VA Medical Center, 3200 Vine St., Cincinnati, OH 45220. Phone: (513) 475-6328. Fax: (513) 475-6415. E-mail: peter.walzer{at}med.va.gov.

Antimicrobial Agents and Chemotherapy, February 2002, p. 514-516, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.514-516.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Cushion, M. T., Walzer, P. D., Ashbaugh, A., Rebholz, S., Brubaker, R., Vanden Eynde, J. J., Mayence, A., Huang, T. L. (2006). In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice.. Antimicrob. Agents Chemother. 50: 2337-2343 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»